ClinicalTrials.gg
CompletedNCT06821061Updated Jan 26, 2026

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

A Phase 1/2 interventional study of Investigational Influenza Vaccine and Investigational COVID-19 Vaccine in Influenza and COVID-19 (Coronavirus Disease 2019), sponsored by BioNTech SE. Completed at 31 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
2,650
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.

Enrollment
124th of 843
2,650 · median 270
Started
2025
with 28 others
Phase 1/2
72 of 966
1 open now
Registered
916th of 966
by date

Among the 966 studies in Influenza, Human with a site in United States, this one is the 124th largest by enrollment of the 843 interventional ones that give a count, is one of 29 that started in 2025, is one of 72 in phase 1/2, and was the 916th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 966 studies in Influenza, Human with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together.

This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.

03

Conditions studied

  • Influenza
  • COVID-19 (Coronavirus Disease 2019)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants 18 years of age or older
  • Healthy participants who are determined by medical history, physical examination (if clinically required), and clinical judgement of the investigator to be eligible for inclusion in the study

Exclusion criteria

Exclusion criteria:

  • Vaccination with any or licensed influenza vaccine within 150 days of enrollment
  • Vaccination with any investigational or licensed COVID 19 vaccine within 150 days of enrollment.
  • Receipt of antiviral therapies for influenza (eg, Tamiflu) within 180 days prior to Day 1.

Refer to the study contact for further eligibility details

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,650 participants (actual)

Study arms

  • Experimental
    Arm A

    Low Dose COVID-19 Vaccine (1a)

    Biological: Investigational COVID-19 Vaccine

  • Experimental
    Arm B

    Low Dose COVID-19 Vaccine ( 1b)

    Biological: Investigational COVID-19 Vaccine

  • Experimental
    Arm C

    Low Dose COVID-19 Vaccine ( 1c)

    Biological: Investigational COVID-19 Vaccine

  • Experimental
    Arm D

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 1)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm E

    Investigational Influenza and COVID-19 Combination Vaccine (Medium Dose Combination 2)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm F

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 3)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm G

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 4)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Active comparator
    Arm H

    Licensed COVID-19 Vaccine

    Biological: Licensed COVID-19 Vaccine

  • Active comparator
    Arm I

    Licensed Influenza Vaccine (1)

    Biological: Licensed Influenza Vaccine 1

  • Experimental
    Arm J

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 5)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm K

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 6)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm L

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 7)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Active comparator
    Arm M

    Licensed COVID-19 Vaccine

    Biological: Licensed COVID-19 Vaccine

  • Active comparator
    Arm N

    Licensed Influenza Vaccine (2)

    Biological: Licensed Influenza Vaccine 2

  • Experimental
    Arm AA

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 6)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm BB

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 4)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm CC

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 7)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm DD

    Investigational Influenza and COVID-19 Combination Vaccine (Medium Dose Combination 2)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm EE

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 3)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Active comparator
    Arm FF

    Licensed COVID-19 Vaccine

    Biological: Licensed COVID-19 Vaccine

  • Active comparator
    Arm GG

    Licensed Influenza Vaccine (3)

    Biological: Licensed Influenza Vaccine 3

  • Active comparator
    Arm HH

    Licensed Influenza Vaccine (2)

    Biological: Licensed Influenza Vaccine 2

  • Experimental
    Arm II

    Low Dose COVID-19 Vaccine ( 1b)

    Biological: Investigational COVID-19 Vaccine

  • Experimental
    Arm JJ

    Low Dose COVID-19 Vaccine ( 1c)

    Biological: Investigational COVID-19 Vaccine

  • Experimental
    Arm KK

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 4)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm LL

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 7)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm MM

    Investigational Influenza and COVID-19 Combination Vaccine (Medium Dose Combination 2)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm NN

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 3)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm OO

    Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 5)

    Combination Product: Investigational Influenza and COVID-19 Combination Vaccine

  • Experimental
    Arm PP

    Medium Dose Investigational Influenza Vaccine (1)

    Biological: Investigational Influenza Vaccine

  • Experimental
    Arm QQ

    High Dose Investigational Influenza Vaccine (2)

    Biological: Investigational Influenza Vaccine

  • Active comparator
    Arm RR

    Licensed COVID-19 Vaccine

    Biological: Licensed COVID-19 Vaccine

  • Active comparator
    Arm SS

    Licensed Influenza Vaccine (3)

    Biological: Licensed Influenza Vaccine 3

Interventions

  • BiologicalInvestigational Influenza Vaccine

    Investigational Influenza Vaccine

  • BiologicalInvestigational COVID-19 Vaccine

    Investigational COVID-19 Vaccine

  • Combination productInvestigational Influenza and COVID-19 Combination Vaccine

    Investigational Combined Influenza and COVID-19 Vaccine

  • BiologicalLicensed Influenza Vaccine 1

    Licensed Influenza Vaccine 1

  • BiologicalLicensed Influenza Vaccine 2

    Licensed Influenza Vaccine 2

  • BiologicalLicensed Influenza Vaccine 3

    Licensed Influenza Vaccine 3

  • BiologicalLicensed COVID-19 Vaccine

    Pfizer-BioNTech COVID-19 Vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting prompted local reactions within 7 days following investigational product administration

    Time frame: Day 7

  2. Percentage of participants reporting prompted systemic events within 7 days following investigational product administration

    Time frame: Day 7

  3. Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration

    Time frame: 1 month

  4. Percentage of participants reporting serious adverse events (SAEs) through 6 months following investigational product administration

    Time frame: 6 months

Secondary outcomes

  1. GMTs before and through 1 month following investigational product administration

    Time frame: Before vaccination through to 1 month after vaccination

07

Study locations

31 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • Alliance for Multispecialty Research, LLC
    Doral, Florida 33172, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Miami Dade Medical Research Institute, LLC
    Miami, Florida 33176, United States
  • Palm Springs Community Health Center
    Miami Lakes, Florida 33014, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Las Vegas Clinical Trials
    North Las Vegas, Nevada 89030, United States
  • Upstate Global Health Institute
    East Syracuse, New York 13057, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Trial Management Associates - Wilmington - Floral Parkway
    Wilmington, North Carolina 28403, United States
  • Centricity Research Columbus Ohio Multispecialty
    Columbus, Ohio 43213, United States
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • AMR Clinical
    Knoxville, Tennessee 37909, United States
  • AMR Clinical
    Knoxville, Tennessee 37920, United States
  • Clinical Research Associates Inc
    Nashville, Tennessee 37203, United States
  • Headlands Horizons, LLC dba Headlands Research-Brownsville
    Brownsville, Texas 78526, United States
  • DM Clinical Research- Cyfair
    Houston, Texas 77065, United States
  • SMS Clinical Research
    Mesquite, Texas 75149, United States
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research
    Tomball, Texas 77375, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
  • Kaiser Permanente Washington Health Research Institute (KPWHRI)
    Seattle, Washington 98101, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Dec 2025, 10 months.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 10 months is below that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 11, 2025
StartActual
Feb 10, 2025
Primary completionActual
Dec 17, 2025
CompletionActual
Dec 17, 2025
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06821061
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Feb 11, 2025
Start date
Feb 10, 2025
Primary completion
Dec 17, 2025
Completion
Dec 17, 2025
Last update
Jan 26, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion